NEOS Investment Management LLC Grows Holdings in IDEXX Laboratories, Inc. $IDXX

NEOS Investment Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 82.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,051 shares of the company’s stock after buying an additional 13,599 shares during the period. NEOS Investment Management LLC’s holdings in IDEXX Laboratories were worth $19,199,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IDXX. Glenview Trust Co grew its position in IDEXX Laboratories by 6.0% in the third quarter. Glenview Trust Co now owns 40,729 shares of the company’s stock worth $26,021,000 after acquiring an additional 2,312 shares in the last quarter. Zions Bancorporation National Association UT lifted its stake in IDEXX Laboratories by 125.5% during the third quarter. Zions Bancorporation National Association UT now owns 345 shares of the company’s stock worth $220,000 after purchasing an additional 192 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of IDEXX Laboratories by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock worth $6,364,638,000 after purchasing an additional 86,040 shares in the last quarter. Fifth Third Bancorp increased its position in shares of IDEXX Laboratories by 23.3% during the 3rd quarter. Fifth Third Bancorp now owns 7,374 shares of the company’s stock valued at $4,711,000 after purchasing an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.98% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

IDXX has been the subject of several research reports. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research note on Monday, November 3rd. UBS Group cut their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a report on Monday, November 3rd. BTIG Research lowered their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $626.17 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market cap of $50.00 billion, a P/E ratio of 47.91, a P/E/G ratio of 3.83 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The firm has a 50-day moving average of $681.98 and a 200-day moving average of $669.66.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company earned $2.53 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.